Recombinant human alkaline phosphatase
Phase 3Terminated 0 views this week 0 watching💤 Quiet
Interest: 22/100
22
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Acute Kidney Injury Due to Sepsis
Conditions
Acute Kidney Injury Due to Sepsis
Trial Timeline
Nov 2, 2020 → Aug 18, 2022
NCT ID
NCT04411472About Recombinant human alkaline phosphatase
Recombinant human alkaline phosphatase is a phase 3 stage product being developed by AM-Pharma for Acute Kidney Injury Due to Sepsis. The current trial status is terminated. This product is registered under clinical trial identifier NCT04411472. Target conditions include Acute Kidney Injury Due to Sepsis.
What happened to similar drugs?
20 of 20 similar drugs in Acute Kidney Injury Due to Sepsis were approved
Approved (20) Terminated (4) Active (0)
✅Modification of Prasugrel based on a biological assay + prasugrel / clopidogrelDaiichi SankyoApproved
Hype Score Breakdown
Clinical
17
Activity
0
Company
5
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04411472 | Phase 3 | Terminated |
Competing Products
20 competing products in Acute Kidney Injury Due to Sepsis